Company / R&D per Share
KalVista Pharmaceuticals, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.69
FY2025
5-year range
$1.44 / $3.93
FY2021-FY2025
Trend
+16.8%
vs FY2024
Sector context
#117 of 208
Health Care
What the data says
At $1.69, KalVista Pharmaceuticals, Inc.'s r&d per share ranks #117 of 208 in the Health Care sector. R&D per Share returned to growth in FY2025 after 3 years of decline, reaching $1.69.
Based on SEC 10-K filings.
1.69 in FY2025 with a 5-year CAGR of -6.7%.
Declined from $2.34 to $1.69 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -19.9%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Sector benchmark
#117 of 208 in Health CareTop 56% of 208This company $1.69 Sector average $12.19
▼
-86.2% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 16.8% year-over-year.
- Ranks #117 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.69 | +16.8% |
| FY2024 | $1.44 | -38.3% |
| FY2023 | $2.34 | -28.7% |
| FY2022 | $3.29 | -16.4% |
| FY2021 | $3.93 | +64.5% |
| FY2020 | $2.39 | +103.7% |
| FY2019 | $1.17 | -22.3% |
| FY2018 | $1.51 | -14.6% |
| FY2017 | $1.77 | -35.2% |
| FY2016 | $2.73 | -91.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026